Drug Trials Snapshots: RYZNEUTA (efbemalenograstim alfa)

RYZNEUTA is a prescription drug that is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ryzneuta